Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
A phase 1/2 trial of Bexobrutideg, Venetoclax, Rituximab and Obinutuzumab in non-Hodgkin lymphoma and chronic lymphocytic leukaemia, run by Nurix Therapeutics, Inc., now recruiting.
Overview
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies is a phase 1/2 interventional study registered as NCT07520006 by Nurix Therapeutics, Inc., with 150 participants planned, started 2026-08 and due to reach its primary completion in 2033-05. Interventions recorded: NX-5948, venetoclax, rituximab and obinutuzumab.
Similar pages
not linked directly; found by shared links- TrialA Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Shares Bexobrutideg, Nurix Therapeutics, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Shares Obinutuzumab, Rituximab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Shares Rituximab, Venetoclax, Non-Hodgkin lymphoma (all types), Chronic lymphocytic leukaemia and the tag pipeline.
- TrialStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Shares Obinutuzumab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Shares Obinutuzumab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Shares Obinutuzumab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Shares Rituximab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Shares Rituximab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.